IMV (IMV) has notable insider buying

IMV (T:IMV)

IMV Inc. (IMV) has a high amount of executive buying compared to its small-cap peers over the past three months. According to recent regulatory filings, two insiders have invested a total amount of $117,122.Albert James Scardino, a Director, acquired 12,900 Common Shares on a direct ownership basis at prices ranging from $4.810USD and $5.297USD through the public market between June 19th, 2018 and June 21st, 2018. The insider also acquired 3,200 Common Shares on a direct ownership basis at prices ranging from $6.340 and $6.388 through the public market on June 21st, 2018. This represents a $104,012 investment into the company's shares and an account share holdings change of 0.9%.

Alfred Smithers, a Director, acquired 1,900 Common Shares on an indirect ownership basis for registered holder Iona Resources Holdings Limited at a price of $6.900 through the public market on June 19th, 2018. This represents a $13,110 investment into the company's shares and an account share holdings change of 2.6%.

Imv Inc, formerly known as Immunovaccine Inc is a Canada-based clinical-stage immuno oncology company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.